Zai Lab Limited (9688.HK)
HKD 20.5
(-3.76%)
HKD 20.5
(-3.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -365.11 Million USD | 6.83% |
| 2022 | -384.65 Million USD | 45.03% |
| 2021 | -689.46 Million USD | -167.49% |
| 2020 | -262.96 Million USD | -29.41% |
| 2019 | -199.43 Million USD | -46.77% |
| 2018 | -138.44 Million USD | -171.24% |
| 2017 | -50.84 Million USD | -40.19% |
| 2016 | -38.33 Million USD | -155.64% |
| 2015 | -16.22 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -72.73 Million USD | -52.63% |
| 2024 Q1 | -48.27 Million USD | 57.72% |
| 2023 Q3 | -88.42 Million USD | -27.37% |
| 2023 Q2 | -69.42 Million USD | 11.49% |
| 2023 FY | - USD | 6.83% |
| 2023 Q1 | -78.43 Million USD | 42.33% |
| 2023 Q4 | -130.55 Million USD | -47.65% |
| 2022 Q1 | -77.75 Million USD | 62.88% |
| 2022 FY | - USD | 45.03% |
| 2022 Q4 | -136 Million USD | -7.63% |
| 2022 Q3 | -126.35 Million USD | -30.46% |
| 2022 Q2 | -96.85 Million USD | -24.57% |
| 2021 FY | - USD | -167.49% |
| 2021 Q2 | -161.39 Million USD | 30.33% |
| 2021 Q3 | -96.07 Million USD | 40.47% |
| 2021 Q4 | -209.44 Million USD | -118.0% |
| 2021 Q1 | -231.65 Million USD | -210.17% |
| 2020 Q2 | -79.26 Million USD | -69.66% |
| 2020 Q3 | -62.28 Million USD | 21.42% |
| 2020 FY | - USD | -29.41% |
| 2020 Q4 | -74.68 Million USD | -19.91% |
| 2020 Q1 | -46.72 Million USD | 10.24% |
| 2019 Q2 | -42.15 Million USD | 0.0% |
| 2019 FY | - USD | -46.77% |
| 2019 Q4 | -52.04 Million USD | 22.93% |
| 2019 Q3 | -67.53 Million USD | -60.2% |
| 2019 Q1 | -42.15 Million USD | 32.79% |
| 2018 Q1 | -20.36 Million USD | -56.15% |
| 2018 Q2 | -20.36 Million USD | 0.0% |
| 2018 Q3 | -34.22 Million USD | -68.11% |
| 2018 Q4 | -62.72 Million USD | -83.26% |
| 2018 FY | - USD | -171.24% |
| 2017 FY | - USD | -40.19% |
| 2017 Q1 | -12.38 Million USD | 9.18% |
| 2017 Q2 | -12.38 Million USD | 0.0% |
| 2017 Q3 | -13.03 Million USD | -5.31% |
| 2017 Q4 | -13.03 Million USD | 0.0% |
| 2016 Q4 | -13.63 Million USD | 0.0% |
| 2016 Q3 | -13.63 Million USD | -146.47% |
| 2016 Q1 | -5.53 Million USD | 0.0% |
| 2016 Q2 | -5.53 Million USD | 0.0% |
| 2016 FY | - USD | -155.64% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 500.192% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 175.003% |